Skip to main content
. Author manuscript; available in PMC: 2021 Jun 14.
Published in final edited form as: Oncogene. 2021 May 12;40(23):3929–3941. doi: 10.1038/s41388-021-01798-2

Figure 6. Induced ERK5 silencing accelerates tumor growth and suppresses FAK phosphorylation in mammary tumor grafts.

Figure 6

MDA-MB-231 cells carrying shERK5i were orthotopically transplanted into the mammary fad pad of CD1 nude mice. (A) Representative bioluminescence images of mammary tumors just before (day 20) and after mice were fed with doxycycline for 12 and 22 days. (B) Tumors were measured on average twice a week for the duration of the experiment. The data presented as fold increase in the volume of tumor size after the introduction of the dox diet at day 20 correspond to the mean ± SD. After 4 weeks, animals in the dox- and dox+ cohorts exhibiting large tumors or a change in normal behavior were humanely culled. Total N number of animals analyzed per condition over the duration of the experiment is indicated. (C) Tumors were collected 4 weeks after exposure to doxycycline and analyzed by immunohistochemistry with a specific antibody to ERK5 or to p-FAK(Y397). Scale bars: (40x) 20 μm.